TECENTRIQ HYBREZA
Sep 23, 2024
Roche’s TECENTRIQ HYBREZA: Setting New Standards as the First Subcutaneous Anti-PD-(L)1 Drug
Better late than never for FDA approval of the first subcutaneous PD-L1 inhibitor—Roche’s TECENTRIQ HYBREZA—after manufacturing delays disrupted the company’s initial launch plans last year. The FDA was originally set to decide on TECENTRIQ’s under-the-skin formulation in September, but Roche’s delivery technolo...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
